CR20210076A - Composiciones de anticuerpo fcrn - Google Patents
Composiciones de anticuerpo fcrnInfo
- Publication number
- CR20210076A CR20210076A CR20210076A CR20210076A CR20210076A CR 20210076 A CR20210076 A CR 20210076A CR 20210076 A CR20210076 A CR 20210076A CR 20210076 A CR20210076 A CR 20210076A CR 20210076 A CR20210076 A CR 20210076A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- molecular weight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/16—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
- H01J49/165—Electrospray ionisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Engineering & Computer Science (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Esta divulgación pertenece a composiciones que comprenden un anticuerpo anti-FcRn, M281. Las composiciones incluyen el anticuerpo entero intacto y tamaños variantes del mismo que no incluyen dos cadenas pesadas de anticuerpo y dos cadenas ligeras de anticuerpo. Por tanto, una composición farmacéutica de M281 puede incluir: un anticuerpo que comprende una cadena pesada que comprende la secuencia de aminoácidos de SEC. ID NO:2 y una cadena ligera que comprende la secuencia de aminoácidos de SEC. ID NO:1, en donde la composición comprende un componente de proteína principal que tiene un peso molecular de 140,000 – 145,000 Da y un componente de proteína secundario con un peso molecular de 118,000 – 120,000 Da.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701367P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042615 WO2020018910A1 (en) | 2018-07-20 | 2019-07-19 | Fcrn antibody compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210076A true CR20210076A (es) | 2021-09-02 |
Family
ID=69165189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210076A CR20210076A (es) | 2018-07-20 | 2019-07-19 | Composiciones de anticuerpo fcrn |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210340251A1 (es) |
| EP (1) | EP3823978A4 (es) |
| JP (1) | JP2021531347A (es) |
| KR (1) | KR20210105873A (es) |
| CN (1) | CN113518783A (es) |
| AU (1) | AU2019307959A1 (es) |
| BR (1) | BR112021000755A2 (es) |
| CA (1) | CA3106670A1 (es) |
| CR (1) | CR20210076A (es) |
| EA (1) | EA202190264A1 (es) |
| IL (1) | IL280278A (es) |
| JO (1) | JOP20210013A1 (es) |
| MX (1) | MX2021000788A (es) |
| PH (1) | PH12021550082A1 (es) |
| SG (1) | SG11202100419UA (es) |
| WO (1) | WO2020018910A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3250610T3 (da) | 2015-01-30 | 2023-10-30 | Momenta Pharmaceuticals Inc | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf |
| CN111712259A (zh) | 2017-12-13 | 2020-09-25 | 动量制药公司 | Fcrn抗体及其使用方法 |
| WO2021022249A1 (en) * | 2019-08-01 | 2021-02-04 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| TW202328184A (zh) * | 2021-08-13 | 2023-07-16 | 大陸商舒泰神（北京）生物製藥股份有限公司 | 特異性識別fcrn的抗體及其用途 |
| WO2024163894A1 (en) | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2722082C (en) * | 2008-04-25 | 2021-11-09 | Christopher Tenhoor | Fc receptor binding proteins |
| JP6104897B2 (ja) * | 2011-06-02 | 2017-04-05 | ダイアックス コーポレーション | Ｆｃレセプター結合タンパク質 |
| AU2014369999B2 (en) * | 2013-12-24 | 2019-12-12 | The Board Of Regents Of The University Of Texas System | FcRn antagonists and methods of use |
| DK3250610T3 (da) * | 2015-01-30 | 2023-10-30 | Momenta Pharmaceuticals Inc | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf |
| DK3491025T3 (da) * | 2016-07-29 | 2024-01-15 | Momenta Pharmaceuticals Inc | Fcrn-antistoffer og anvendelsesmetoder heraf |
-
2019
- 2019-07-19 JP JP2021526405A patent/JP2021531347A/ja active Pending
- 2019-07-19 WO PCT/US2019/042615 patent/WO2020018910A1/en active Application Filing
- 2019-07-19 KR KR1020217003739A patent/KR20210105873A/ko unknown
- 2019-07-19 CR CR20210076A patent/CR20210076A/es unknown
- 2019-07-19 AU AU2019307959A patent/AU2019307959A1/en active Pending
- 2019-07-19 US US17/260,334 patent/US20210340251A1/en active Pending
- 2019-07-19 BR BR112021000755-5A patent/BR112021000755A2/pt unknown
- 2019-07-19 CA CA3106670A patent/CA3106670A1/en active Pending
- 2019-07-19 CN CN201980061787.3A patent/CN113518783A/zh active Pending
- 2019-07-19 MX MX2021000788A patent/MX2021000788A/es unknown
- 2019-07-19 JO JOP/2021/0013A patent/JOP20210013A1/ar unknown
- 2019-07-19 SG SG11202100419UA patent/SG11202100419UA/en unknown
- 2019-07-19 EA EA202190264A patent/EA202190264A1/ru unknown
- 2019-07-19 EP EP19838652.6A patent/EP3823978A4/en active Pending
-
2021
- 2021-01-13 PH PH12021550082A patent/PH12021550082A1/en unknown
- 2021-01-19 IL IL280278A patent/IL280278A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021000788A (es) | 2021-07-21 |
| CA3106670A1 (en) | 2020-01-23 |
| US20210340251A1 (en) | 2021-11-04 |
| JP2021531347A (ja) | 2021-11-18 |
| KR20210105873A (ko) | 2021-08-27 |
| AU2019307959A1 (en) | 2021-02-04 |
| WO2020018910A1 (en) | 2020-01-23 |
| SG11202100419UA (en) | 2021-02-25 |
| BR112021000755A2 (pt) | 2021-04-13 |
| CN113518783A (zh) | 2021-10-19 |
| EP3823978A4 (en) | 2022-12-14 |
| EP3823978A1 (en) | 2021-05-26 |
| IL280278A (en) | 2021-03-25 |
| EA202190264A1 (ru) | 2021-05-20 |
| JOP20210013A1 (ar) | 2021-01-19 |
| PH12021550082A1 (en) | 2021-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210076A (es) | Composiciones de anticuerpo fcrn | |
| AR119682A2 (es) | Composiciones inmunogénicas de antígenos de staphylococcus aureus | |
| CO2019006565A2 (es) | Novedoso conjugado de amanitina | |
| IL200373A (en) | A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans | |
| CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
| SG10201909173PA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| RU2018122823A (ru) | Мутанты белка f rsv | |
| BR112018015754A2 (pt) | anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1 | |
| MX2022002111A (es) | Novedosos anticuerpos anti-cldn18.2. | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| BR112018003594A2 (pt) | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados | |
| EA202190335A1 (ru) | Композиции антител против fcrn и способы их применения | |
| PE20181176A1 (es) | Composiciones biofarmaceuticas | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
| EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
| ES2530670T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| MX2023008423A (es) | Anticuerpos anti-gremlin1 novedosos. | |
| GB2543713A (en) | Polymeric proteins and uses thereof | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| BR112016019332A2 (pt) | anticorpo pai-1 anti-humano inovador | |
| MX2024004132A (es) | Composiciones de moldeo de poliamida para materiales de vidrio compuestos. | |
| NZ744289A (en) | Composition containing amino acids |